• Mental Health, Quality of Life, and Work Functioning of Parents of Children Who Have Died of Spinal Muscular Atrophy

    Feb 1, 2026, 00:00

  • Mapping Methodologies for Economic Evaluation of Digital Health Technologies: A Scoping Review

    Feb 1, 2026, 00:00

  • Should Early-Stage NIH Funding Influence Pharmaceutical Drug Pricing?

    Feb 1, 2026, 00:00

  • Derivation of Meaningful Change Thresholds for European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 in Patients With Small-Cell Lung Cancer

    Feb 1, 2026, 00:00

  • EQ-5D-5L in Multiple Sclerosis: Estimated Utility Values, Minimal (Clinically) Important Changes, and Direct and Indirect Influences Over Time

    Feb 1, 2026, 00:00

  • What Costs and Benefits Should be Counted in Health Technology Assessments and Guidelines? The NICE Perspective

    Feb 1, 2026, 00:00

  • Means Can Be Deceiving: Comparing and Contrasting Risk Tolerance Estimates From a Discrete-Choice Experiment and a Threshold Technique Exercise

    Feb 1, 2026, 00:00

  • Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Special Interest Group Report

    Feb 1, 2026, 00:00

  • The Cost-Effectiveness of Community Health Workers in Primary Health Care: A Systematic Review

    Feb 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children With Asthma

    Feb 1, 2026, 00:00

  • Comparing Psychometric Properties of 6 of the 5-Level and 3-Level EQ-5D Bolt-Ons in a Large, Multinational, Longitudinal General Population Sample

    Feb 1, 2026, 00:00

  • PROM-ising Progress? Trends in Patient- and Clinician-Reported Outcome Measures in US Food and Drug Administration Orphan Drug Labels

    Feb 1, 2026, 00:00

  • Preferences for Adopting Artificial Intelligence in Radiation Therapy Treatment: A Discrete Choice Experiment

    Feb 1, 2026, 00:00

  • Long-Term Outcomes and Cost-Effectiveness of Artificial Intelligence for Breast Cancer Screening: A Modeling Study

    Feb 1, 2026, 00:00

  • Cost-Effectiveness of Reorganizing the Approach to Diabetes Through the Application of Registries: An Innovative Model to Organize Diabetes Care in First Nations Communities in Canada

    Feb 1, 2026, 00:00

  • A Patient Preference-Weighted Quantitative Benefit-Risk Analysis of Ritlecitinib for Alopecia Areata to Inform Medical Decision Making

    Feb 1, 2026, 00:00

  • How Do Different Health States Impact Preferences for Social-Care-Related Quality of Life: An Exploration of EQ-5D-5L and Adult Social Care Outcomes Toolkit Using a Vignette Approach

    Feb 1, 2026, 00:00

  • Development of a Preference Weighting System for the Parent-Proxy Child Chronic Cough Quality-of-Life Instrument

    Feb 1, 2026, 00:00

  • Hospital and Regional-Level Factors Associated With Negotiated Payer Rates for Hip Fracture Fixation: A Multistate Analysis

    Feb 1, 2026, 00:00

  • Editorial Board

    Jan 23, 2026, 08:45

  • Table of Contents

    Jan 23, 2026, 08:41

  • Table of Contents

    Jan 5, 2026, 12:03

  • Methodological Insights From Health Valuation Studies in Low- and Middle-Income Countries: A Scoping Review

    Jan 1, 2026, 00:00

  • Pharmaceutical Pricing Evidence From a Healthcare System With Multiple Cost-per-Quality-Adjusted Life-Year Thresholds

    Jan 1, 2026, 00:00

  • Comparing Adolescent and Adult Preferences for EQ-5D-Y-3L Health States in Hong Kong

    Jan 1, 2026, 00:00

  • A Head-to-Head Comparison of the Psychometric Properties of the EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D in Children Aged 8 to 18 Years With Eczema

    Jan 1, 2026, 00:00

  • Operationalizing Distributional Cost-Effectiveness in Genomic Medicine: A United States–Focused Comment

    Jan 1, 2026, 00:00

  • Unlocking Patient Preferences: The Potential of Stated-Preference Methods in Clinical Decision Making

    Jan 1, 2026, 00:00

  • Implications of Value Set Choice on EQ-5D-Y-3L Child and Proxy Health-Related Quality of Life Ratings: What to Do When a Country-Specific “Y” Value Set Is Unavailable?

    Jan 1, 2026, 00:00

  • Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation Program

    Jan 1, 2026, 00:00

  • Clinical Outcomes and Measures for Vaginal Relaxation Syndrome: A Systematic Review

    Jan 1, 2026, 00:00

  • Application of International Reference Pricing Rules to Forecast Pharmaceutical Launch Prices in 5 European Countries

    Jan 1, 2026, 00:00

  • Incorporating Informal Caregiving Time Into Cost-Effectiveness Analysis for Adults Aged 50 and Older: Estimating From Health-Related Quality of Life and Functional Status

    Jan 1, 2026, 00:00

  • The Cost-Effectiveness of Collagenase Injection Versus Limited Fasciectomy for Moderate Dupuytren’s Contracture: An Economic Evaluation of the Dupuytren’s Interventions Surgery Versus Collagenase Trial and a Decision Analytical Model

    Jan 1, 2026, 00:00

  • Toward a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report

    Jan 1, 2026, 00:00

  • Adult Social Care Outcomes Toolkit and ICEpop Capability Measure in Decision Making: A Review of NICE Social Care and Public Health Guidelines

    Jan 1, 2026, 00:00

  • Integrating Price Benchmarks and Comparative Clinical Effectiveness to Predict Initial Price Offers for Medicare Drug Price Negotiation (Initial Price Applicability Year 2027)

    Jan 1, 2026, 00:00

  • Predicting Healthcare Utilization Outcomes With Artificial Intelligence: A Large Scoping Review

    Jan 1, 2026, 00:00

  • Health Inequality Aversion in the United States

    Jan 1, 2026, 00:00

  • A Generalized Risk-Adjusted Cost-Effectiveness Economic Model for Measuring the Value of Interventions That Delay Mobility Impairment Across Neurological Conditions

    Jan 1, 2026, 00:00

  • Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions

    Jan 1, 2026, 00:00

  • Editorial Board

    Jan 1, 2026, 00:00

  • Disclaimer

    Dec 19, 2025, 11:50

  • Editorial Board

    Dec 16, 2025, 09:49

  • EPH269 Unlocking Insights in Prescription Data in England: The Power of the Prescribing Episode Statistics (PES) Database

    Dec 1, 2025, 00:00

  • HSD100 Rising Polypharmacy Trends and Associated Factors in Chinese Adults With Diabetes: A Population-Based Cohort Study

    Dec 1, 2025, 00:00

  • HPR207 The Intercept of Real-World Evidence (RWE) Health Equity and Health Technology Assessment (HTA): A Structured Literature Review of Health Policy and Methodological Guidance

    Dec 1, 2025, 00:00

  • HPR218 Through a Glass Darkly: The What, How, and What Now for Global Net Price Transparency

    Dec 1, 2025, 00:00

  • HTA311 Targeted Review of mITT vs. ITT Data in CAR-T Submissions

    Dec 1, 2025, 00:00

  • EPH124 Heatstroke Is Associated With an Increased Risk of Chronic Headache: A Retrospective Cohort Study in Germany

    Dec 1, 2025, 00:00

  • EE491 Health Economic Evaluation Model for Pancreatic Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • EPH180 Pharosight: A Shiny-Based Interactive Platform With LLM-Enhanced Analyses and Predictive Modeling for Real-World Prescription Data

    Dec 1, 2025, 00:00

  • MSR212 Use of a Nonparametric Bayesian Method to Model Health State Preferences: An Application to UAE EQ-5D-5L Valuations

    Dec 1, 2025, 00:00

  • SA12 An Interactive Tool to Select Indirect Treatment Comparison Methods for Rapid Feasibility Assessment

    Dec 1, 2025, 00:00

  • EPH211 Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy Patients in the Brazilian Public Health System: A Real-World Study

    Dec 1, 2025, 00:00

  • HTA291 Rising EAP Rejection Rates and Their Impact on Drug Access in France

    Dec 1, 2025, 00:00

  • HPR24 Analysis of Historical European Medicines Agency (EMA) Marketing Authorization (MA) Timelines: Will EU Joint Clinical Assessment (JCA) Timelines Be Longer Than Expected?

    Dec 1, 2025, 00:00

  • EE152 Considerations for Modeling Caregiver Spillover Within Economic Evaluations for Neurological Disorders: Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy (DMD), and Multiple Sclerosis (MS)

    Dec 1, 2025, 00:00

  • EE649 Requirements for Payer Recognition of Disease-Modifying Effect in New Drug Launches

    Dec 1, 2025, 00:00

  • PCR85 Evaluation and Validation of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ)

    Dec 1, 2025, 00:00

  • EE272 Cost-Effectiveness of rhTNK-tPA vs. rt-PA for Acute Ischemic Stroke Patients Within 4.5H of Symptom Onset in China

    Dec 1, 2025, 00:00

  • P32 The Healthcare Improvement Scotland Think Frailty Tool: A Preliminary Psychometric Evaluation

    Dec 1, 2025, 00:00

  • HTA139 Evolution of Acceptance of Evidence and PMA Outcomes by HTA Authorities for ATMPs in the EU4 and the UK 2017-2025

    Dec 1, 2025, 00:00

  • EE104 Budget Impact of an Ambulatory Minimally Invasive Surgical Treatment in an Italian Public Hospital

    Dec 1, 2025, 00:00

  • P63 No Strong Preference? Acceptance of the Quantitative Incorporation of Patient Preference in Economic Modeling in Past NICE Technology Appraisals

    Dec 1, 2025, 00:00

  • HSD93 Real-World Differences in Breast Cancer Management by Detection Method: A Czech National Analysis

    Dec 1, 2025, 00:00

  • EE571 Management of Moderate-to-Highly Exuding Leg Ulcers with Polyacrylate Dressings vs. Foam Dressings in Spanish Settings: An Early Stage Cost-Effectiveness and Budget-Impact Analysis

    Dec 1, 2025, 00:00

  • MSR45 Bayesian Parametric Mixture Cure Survival Models With Delayed Treatment Effects and Application to Targeted Therapies in Advanced Ovarian Cancer

    Dec 1, 2025, 00:00

  • EPH242 The Importance and Recognition of Hypo and Hyperkalemia in Prehospital Care

    Dec 1, 2025, 00:00

  • PCR75 Enhancing Understanding of Quality of Life in Multiple Sclerosis Through Social Listening: Complementing Traditional HRQoL Measures

    Dec 1, 2025, 00:00

  • HPR98 Fragmentation in Access Pathways: A Review of HTA and Decision-Making Processes for Medicines in Finland

    Dec 1, 2025, 00:00

  • HPR200 The Evolving Horizon of Oncology: Predicting the Impact of the EU HTA Regulation for 2026-2029

    Dec 1, 2025, 00:00

  • EE450 Evolving Payer Preferences for Health Economic Information and Communication in the US

    Dec 1, 2025, 00:00

  • HTA190 HTA Submission Trends for EMA-Approved Oncology NASs Prior to the EU HTA Regulation 2018-2023

    Dec 1, 2025, 00:00

  • HSD106 The DM77 and Rare Diseases: Analysis of Regional Legislation in Italy

    Dec 1, 2025, 00:00

  • PCR72 Enhancing Equity in Cancer Clinical Trials: A Synthesis of Patient-Reported Barriers and Sustainable Solutions

    Dec 1, 2025, 00:00

  • EE45 An Early Cost-Effectiveness Model for a Digital Community-Based Approach for Streamlined Audiology Care

    Dec 1, 2025, 00:00

  • PCR162 Multinational Qualitative Testing of the Experimental EuroQol Toddler and Infant Populations (EQ-TIPS) Instrument

    Dec 1, 2025, 00:00

  • HTA341 Treatment Effect Extrapolation Assumptions in NICE Highly Specialized Technology Appraisals

    Dec 1, 2025, 00:00

  • EE213 Cost-Effectiveness Analysis of Oral Semaglutide As a Third-Line Treatment for Patients With Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • HPR25 Analysis of the Impact of the TelE-Medicine Program for Medically Underserved Area on Hospitalization Rates Among Diabetic Patients in Medically Underserved Areas

    Dec 1, 2025, 00:00

  • EPH55 COVID-19 mRNA-1273 Vaccination in the UK: A Comparative Modeling Study of Alternative Eligibility Criteria

    Dec 1, 2025, 00:00

  • SA36 Economic Burden Utilities and Cost-Effectiveness of Perioperative Immunotherapies for Early Stage Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • HTA159 Funding the Fight Against Antimicrobial Resistan Learnings From the UK and Sweden’s Pilot Incentive Programs

    Dec 1, 2025, 00:00

  • HSD123 Value-Based Decision Making in a Social Security Provider in Argentina for Oncology and Oncohematology Drugs

    Dec 1, 2025, 00:00

  • HTA307 Surrogate Outcome Validation Within the New EU HTA Guidance Framework: Practical Considerations From an Industry Perspective Based on Experience From HTA Germany

    Dec 1, 2025, 00:00

  • HTA32 Analysis of Pros Included in the HTA Assessment of Conditionally Approved Oncology Drugs in the UK, Italy, and Germany

    Dec 1, 2025, 00:00

  • RWD144 Real-World Healthcare Resource Utilization and Related Costs Associated With Schizophrenia in the Brazilian Private Market

    Dec 1, 2025, 00:00

  • RWD19 Assessing Patient Access to Psoriasis Treatments in Central, South, and Eastern European Countries: Insights and Disparities?

    Dec 1, 2025, 00:00

  • HPR232 Use of High-Cost Medicines in Secondary Care Settings in the English National Health Service

    Dec 1, 2025, 00:00

  • EE204 Cost-Effectiveness Analysis of Image-Guided Ablation vs. Conventional Ablation in Patients With Recurrent Ventricular Tachycardia: Results From the inEurHeart Trial

    Dec 1, 2025, 00:00

  • SA35 Disease-Free Survival as a Surrogate Endpoint for Overall Survival in Patients With Adjuvant Treatments for Completely Resected Stage I-III Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analyses

    Dec 1, 2025, 00:00

  • EE619 Productivity Losses Due to Ill Health Among Adults Aged 50 and Older in Greece

    Dec 1, 2025, 00:00

  • HTA151 From French Early Access to Regular Reimbursement: How Do Prices Shift Post-HTA?

    Dec 1, 2025, 00:00

  • EE681 Systems Simulation Methods for the Economic Evaluation of Non-Medicines and Nonsurgical Interventions: A Systematic Literature Review of Quality and Methods for Reproducing Complexity in Health and Health Behaviors

    Dec 1, 2025, 00:00

  • EE477 Forecasting Uptake of Novel Drugs Used for Atopic Dermatitis in Sweden Based on Historic RWE

    Dec 1, 2025, 00:00

  • EPH134 Impact of Delayed or Missing Diagnosis of Chronic Kidney Disease

    Dec 1, 2025, 00:00

  • EE740 Uncovering the Cost Landscape of Congenital Heart Disease (CHD) With a Life Course Perspective: A Systematic Review of Healthcare Utilization by Lesion Type and Age

    Dec 1, 2025, 00:00

  • MSR161 Overfitting Mitigation in Neural Networks: Could Ergodic Regularization Be the Future of AI?

    Dec 1, 2025, 00:00

  • HPR227 Understanding Reimbursement and Access Policies for Immunoglobulins and Other Plasma-Derived Medicinal Products Across Europe

    Dec 1, 2025, 00:00

  • HSD59 How the NHS Can Optimize Health Outcomes in a Time of Financial Constraint

    Dec 1, 2025, 00:00

  • EE400 Economic Impact of Lenalidomide-Refractory Multiple Myeloma in Finland: Insights From Real-World Data

    Dec 1, 2025, 00:00

  • RWD166 Real-World Utilization Pattern of GLP-1 Receptor Agonists in German Outpatient Care

    Dec 1, 2025, 00:00

  • EE90 Budget Impact Analysis of Introducing the Elecsys® PRO-C3 Assay as Part of the ADAPT Algorithm for Assessing the Severity of Hepatic Fibrosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the UK

    Dec 1, 2025, 00:00

  • HTA281 Recent Changes in HTA and Reimbursement Requirements: Learnings for Global Dossiers

    Dec 1, 2025, 00:00

  • HTA305 Supplementing Single-Arm Trial Data in NICE Submissions: Are Synthetic Approaches Leading the Charge?

    Dec 1, 2025, 00:00

  • CO233 The Association Between COVID-19 Vaccination and the Healthcare Resource Use Related to COVID-19 in Typical Rural Residents in Japan

    Dec 1, 2025, 00:00

  • EE404 Economic Value of Dupilumab in Preventing and Treating Comorbid Asthma in Pediatric Patients With Atopic Dermatitis: A Cost-Offset Model From the Italian Payer Perspective

    Dec 1, 2025, 00:00

  • EE196 Cost-Effectiveness Analysis of Dostarlimab Plus Carboplatin-Paclitaxel in Primary Advanced or Recurrent Endometrial Cancer With Deficient Mismatch Repair (dMMR) and High Microsatellite Instability (MSI-H) in France

    Dec 1, 2025, 00:00

  • HSD54 Guideline-Driven Off-Label Oncology Use: The Role of Clinical Evidence and Reimbursement Dynamics in the EU4+UK, Switzerland, and Canada

    Dec 1, 2025, 00:00

  • EE264 Cost-Effectiveness of Nivolumab Plus Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable NSCLC in Greece

    Dec 1, 2025, 00:00

  • HPR33 Barriers and Facilitators Influencing the Development of Complex Generics: An Exploratory Study

    Dec 1, 2025, 00:00

  • MSR158 Optimizing MASLD Follow-up Strategies Under Adherence Uncertainty: A Game Theory and Signaling Approach

    Dec 1, 2025, 00:00

  • CO169 Network Meta-Analysis NMA of Clinical Effectiveness of Second-Line (2L+) Treatments in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

    Dec 1, 2025, 00:00

  • RWD31 Characterization of a Large-Scale Real-World Data Sour Impact of Linking Closed Claims With Electronic Health Record Data

    Dec 1, 2025, 00:00

  • HTA299 Simulated Treatment Comparisons in NICE Technology Appraisals: Frequency Trends and Implications

    Dec 1, 2025, 00:00

  • HSD111 Towards Quantifying the Impact of Hypofractionation vs. Standard Radiotherapy Treatment Regimens for Cancer on Costs Workflow and the Environment

    Dec 1, 2025, 00:00

  • HPR5 A Comparative Analysis of Similarities and Differences of RWE Standards Across Regulatory and Health Technology Assessment Bodies

    Dec 1, 2025, 00:00

  • CO77 Comparative Efficacy of Ongericimab Versus Six PCSK9 Inhibitors in Treating Hypercholesterolemia or Mixed Dyslipidemia: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • EPH129 Hospitalization and Healthcare Consumption Burden of Respiratory Syncytial Virus (RSV) in Adults Over 50 years in France (RESVYR Study)

    Dec 1, 2025, 00:00

  • PCR18 Are Discrete Choice Experiment Results Robust to Omitted Attributes? Evidence From a Vaccine Study

    Dec 1, 2025, 00:00

  • EE327 Development of a Discrete Event Simulation Model to Explore the Potential Cost-Effectiveness for Cancer Early Detection Testing in Female BRCA Carriers

    Dec 1, 2025, 00:00

  • EE179 Cost of Care for Relapsing/Remitting Multiple Sclerosis Treatments: A Pharmacoeconomic Evaluation From the Spanish Healthcare System Perspective

    Dec 1, 2025, 00:00

  • HTA129 Evaluating an Augmented Reality Software for Mechanical Thrombectomy Using the Lean Assessment Process Methodology: Identifying Clinical Needs, Stakeholder Acceptance, and Adoption Barriers in the NHS

    Dec 1, 2025, 00:00

  • EPH230 The Changing Prevalence of Multicomorbid Patients in the US

    Dec 1, 2025, 00:00

  • HPR27 Annual Change in Türkiye’s Reimbursement List: A Comparative Descriptive Analysis of the 2023 and 2024 SUT Annex 4-A Lists

    Dec 1, 2025, 00:00

  • CO3 A Systematic Literature Review and Network Meta-Analysis of Once-Weekly Icosema With Daily Fixed-Dose Combinations of Basal Insulin and GLP-1 RA in Patients With Type 2 Diabetes After 52 Weeks of Treatment

    Dec 1, 2025, 00:00

  • SA102 Viable Rate of Return for Social Impact Bonds Supporting Research and Development of Gene Therapies for Rare Conditions

    Dec 1, 2025, 00:00

  • HTA368 When Less Is More? Learnings From a Recent NICE Submission Utilizing a Novel Predictive Individual-Level Surrogacy Approach to Predict Overall Survival (OS) in the Absence of Trial-Level Evidence

    Dec 1, 2025, 00:00

  • EE482 Half-Cycle Correction: It’s Time to Let It Go

    Dec 1, 2025, 00:00

  • HPR153 Orphan Drugs Availability in Israel: A Base for Policy Development

    Dec 1, 2025, 00:00

  • MSR38 Assessing Accuracy of Unsupervised Large Language Model Tools for Identifying Key Criteria Supporting Abstract Screening

    Dec 1, 2025, 00:00

  • MSR41 Assessing the Psychometric Performance of the Experimental EQ-TIPS V20 in Assessing the Health-Related Quality of Life of Stunted Children in Laos

    Dec 1, 2025, 00:00

  • MSR42 Automating PICOs Criteria Assessment in Systematic Reviews With LLMs: Insights From Two Case Studies

    Dec 1, 2025, 00:00

  • EE410 Enhancing Healthcare Cost Communication Through Visualization: A Decision Tree Framework

    Dec 1, 2025, 00:00

  • MSR34 Artificial Intelligence Detection of National Clinical Practice Gaps in Hormone-Sensitive Prostate Cancer (HSPC) in Brazil: A Patient-Centered Framework

    Dec 1, 2025, 00:00

  • EPH108 Exploring the Impact of Patient Characteristics and Reporting Period on Adverse Drug Withdrawal Event Signals in the FAERS Database: A Stratified Disproportionality Analysis Study

    Dec 1, 2025, 00:00

  • EE486 Healthcare Resource Utilization and Costs Among Various Disease States in Adults With Hepatitis Delta Virus in Inpatient and Outpatient Settings in the United States

    Dec 1, 2025, 00:00

  • HTA135 Evaluating the Role of Societal Perspectives in the EU Joint Clinical Assessment Framework and in EU-27 Health Technology Assessment Guidelines

    Dec 1, 2025, 00:00

  • EE682 Targeted Literature Review Informing Economic Model Structures in Atherosclerotic Cardiovascular Disease

    Dec 1, 2025, 00:00

  • SA98 Trends in Vaccination at Pharmacies by Race Among Medicaid Recipients: A Claims Analysis

    Dec 1, 2025, 00:00

  • RWD126 MIRROR KEYNOTE: Generating Real-World External Control Arms in Non-Small Cell Lung Cancer Using a Curated Database

    Dec 1, 2025, 00:00

  • PCR138 Increased Adherence to Biologic Therapies Leads to Lower All-Cause and Asthma-Related (HCRU) Costs in Severe Asthma

    Dec 1, 2025, 00:00

  • EPH201 Quantification of the HPV-Attributable Cancer Mortality in Gree Years of Life Lost and Productivity Costs

    Dec 1, 2025, 00:00

  • PCR129 Impact of Glucagon-Like Peptide-1 Treatments on Patient-Reported Outcomes in Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • PT4 Developing a Novel Model Structure for Evaluating Treatment Sequences in Oncology Pathways: A Pilot in Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • EE617 Procalcitonin-Guided Antimicrobial Stewardship for Sepsis and Lower Respiratory Tract Infections: A Budget Impact Analysis for the Perspective of the Patients in India

    Dec 1, 2025, 00:00

  • HSD79 Optimizing Workforce Efficiency and Reducing Waiting Lists Through Remote Monitoring in Obstructive Sleep Apnea (OSA) Care in NHS

    Dec 1, 2025, 00:00

  • EE511 Healthcare Resource Utilization and Costs Among Bacillus Calmette-Guérin (BCG)-Experienced or Unresponsive Patients With Papillary-Only High-Risk Non–Muscle Invasive Bladder Cancer

    Dec 1, 2025, 00:00

  • EE418 Estimating Costs Avoided by Preventing Recurrences With a BRCA Testing Strategy in High-Risk HER2-Negative Adjuvant Breast Cancer Patients in Spain

    Dec 1, 2025, 00:00

  • EE439 Evaluating the Costs of Perioperative Iron-Deficiency Anemia Management in China: A Comparison of Ferric Derisomaltose, Ferric Carboxymaltose, and Usual Care

    Dec 1, 2025, 00:00

  • HPR216 The Value of Rare Pediatric Disease Designation Program for Decision Making by Drug Developers

    Dec 1, 2025, 00:00

  • P23 Optimal Hemoglobin Thresholds for ICU Transfusion: A Target Trial Emulation in a Large Electronic Medical Record-Based Real-World Database

    Dec 1, 2025, 00:00

  • HTA92 Cost-Effectiveness Analysis of Aztreonam Avibactam (ATMAVI) ± Metronidazole (MTZ) for the Treatment of Complicated Intra-Abdominal Infections (cIAIs) and Ventilator-Associated Hospital-Acquired Pneumonia (HAP/VAP) Caused by Suspected ...

    Dec 1, 2025, 00:00

  • CO91 Efficacy and Safety of Biologics to Treat Adults With Active Radiographic Axial Spondyloarthritis: Systematic Review and Bayesian Network Meta-Analysis

    Dec 1, 2025, 00:00

  • CO199 Real Option Value of Sotatercept in Pulmonary Arterial Hypertension: A Health Economic Perspective on Future Treatment Opportunities

    Dec 1, 2025, 00:00

  • HSD9 Assessing the Impact of Technology-Powered, Pharmacy- and Nursing-Supported Direct Oral Anticoagulant Management

    Dec 1, 2025, 00:00

  • PCR98 Factors Influencing Intent to Vaccinate Against Respiratory Syncytial Virus (RSV) Among Older Adults in Australia, Hong Kong, Japan, New Zealand, South Korea, Singapore, and Taiwan

    Dec 1, 2025, 00:00

  • HPR53 Deliverables From 10 Years' Implementation of a National Health Technology Assessment System: Outcomes Sustainability Efficiency, Access, and Equity

    Dec 1, 2025, 00:00

  • EE64 Assessing the Value of Purewick™ System for the Management of Female Patients With Urinary Incontinence in the Nonacute Setting: Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • RWD93 Healthcare Resource Utilization Before and After Cardiovascular Disease Diagnosis in the NHS: A Descriptive Cohort Study

    Dec 1, 2025, 00:00

  • EE636 Real-World Evidence on Healthcare Resource Utilization (HCRU) and Economic Burden of Patients With COPD Treated With Dual or Triple Therapy: Stratified Analysis by Blood Eosinophil Count and Exacerbation Phenotype in the BREATHE-IN St ...

    Dec 1, 2025, 00:00

  • HTA322 The Key Role of Social Participation in Health Technology Assessment: Experiences From South American Countries

    Dec 1, 2025, 00:00

  • SA11 An AI-Enhanced Targeted Literature Review Workflow to Support Inclusive Research Practices and Population Science Research: A Human-in-the-Loop Approach

    Dec 1, 2025, 00:00

  • CO35 Burden of Illness Among Patients With Transfusion Dependent Beta-Thalassemia in Spain: A Registry-Based Study

    Dec 1, 2025, 00:00

  • CO234 The Association of Glucagon-Like Peptide-1 Receptor Agonists With Hepatopancreatobiliary Diseases in Individuals With Type 2 Diabetes Mellitus

    Dec 1, 2025, 00:00

  • RWD125 Millennial Medical Record (MMR) Data Profile: A Japanese Electronic Medical Records (EMRs) Database Utilizing Unstructured Data for Lung Cancer Research

    Dec 1, 2025, 00:00

  • PCR64 Development of Two Versions of a Patient-Reported Outcome Measure to Evaluate Participant Experience and Satisfaction During the Intervention and Analytical Treatment Interruption Periods of Cure-Related and Other HIV Trials

    Dec 1, 2025, 00:00

  • CO201 Real-World Clinical and Economic Outcomes of Time in Range in Association With Diabetic Retinopathy Among Patients With Type I Diabetes

    Dec 1, 2025, 00:00

  • HPR154 Patient Pathways to Accessing Unregistered Medicines in Low-Priority Launch Markets

    Dec 1, 2025, 00:00

  • MSR165 Performance Evaluation of AI-Assisted Systematic Literature Review for Studies on Burden of HPV-Associated Head and Neck Cancers

    Dec 1, 2025, 00:00

  • EE113 Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in Italy

    Dec 1, 2025, 00:00

  • EE73 Bimekizumab Budget Impact Analysis for the Treatment of Patients With Moderate-to-Severe Hidradenitis Suppurativa (HS) in Greece

    Dec 1, 2025, 00:00

  • HTA63 Building the Bridge to Access: Leveraging RWE From Early Access Schemes to Reimbursement in Gene and Cell Therapies

    Dec 1, 2025, 00:00

  • PCR230 The Estimation of Utility Weights From the Rett Syndrome Behavior Questionnaire

    Dec 1, 2025, 00:00

  • MSR145 Measuring the Elephant in the Room: Quantifying Legal Barriers to AI Processing of Full-Text in Systematic Reviews

    Dec 1, 2025, 00:00

  • RWD95 Healthcare Resource Utilization in Adults with Type 1 Diabetes Who Have a Prior Type 2 Diabetes Misdiagnosis and Recorded HbA1c in a US Managed Care Population

    Dec 1, 2025, 00:00

  • HTA64 Canadian HTA Decisions (2020-2023): Comparing CDA-AMC and INESSS Recommendations on Drug Reimbursement

    Dec 1, 2025, 00:00

  • HPR181 Semaglutide in Transition: A Nationwide Register-Based Study in Finland 2019-2024

    Dec 1, 2025, 00:00

  • SA105 Where Is AI in Evidence Synthesis for NICE HTA Submissions?

    Dec 1, 2025, 00:00

  • EE217 Cost-Effectiveness Analysis of Quizartinib for Adult Patients With Newly Diagnosed FLT3-ITD+ Acute Myeloid Leukemia (AML) in Spain

    Dec 1, 2025, 00:00

  • EE378 Economic Evaluation of Contemporary First-Line (1L) Treatments for Locally Advanced or Metastatic Urothelial Carcinoma La/mUC in Fran A Sensitivity Analysis

    Dec 1, 2025, 00:00

  • EE55 Assessing Conditional Cash Transfers for Tuberculosis Patients in India: An Extended Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • PCR99 Framing Matters! Implications of Loss Aversion for Communicating Benefits to Patients in Preference Studies (and Beyond)

    Dec 1, 2025, 00:00

  • MSR167 Piloting a GenAI Agent for Structured Quality Appraisal of Network Meta-Analyses Using the ISPOR-AMCP-NPC Checklist

    Dec 1, 2025, 00:00

  • P37 Advancing Preference Elicitation Techniques for Rare Diseases and Limited Sample Populations

    Dec 1, 2025, 00:00

  • SA60 Let LAMBA Do the Work: Can We Reduce Reliance on VBA in Health Economic Models?

    Dec 1, 2025, 00:00

  • MSR164 Patients With Lupus Across Germany: An AI/ML Driven Method to Maximize Patient Selection From Longitudinal Prescription Data (IQVIA LRx)

    Dec 1, 2025, 00:00

  • HPR82 Evolution of Negotiations and Contracts for Reimbursement of Pharmaceuticals in Greece Between 2020 and 2025: Onwards and Upwards

    Dec 1, 2025, 00:00

  • HTA212 Is Protocolized Stopping Lifelong Therapy With Eculizumab With Disease Monitoring and Retreatment for Eligible Atypical Hemolytic Uremic Syndrome (aHUS) Patients Cost-Effective? An Economic Evaluation of the SETS aHUS Trial

    Dec 1, 2025, 00:00

  • Dec 1, 2025, 00:00

  • EE224 Cost-Effectiveness and Budget Impact of Increasing Peritoneal Dialysis Utilization Among End-Stage Kidney Disease Patients in South Korea

    Dec 1, 2025, 00:00

  • MSR77 Differential Responsiveness and Minimally Important Difference of EQ-5D: Truth or Artifact?

    Dec 1, 2025, 00:00

  • CO78 Dupilumab Improves Lung Function and Asthma Control While Reducing Systemic Corticosteroid Use in Patients With Allergic Bronchopulmonary Aspergillosis: The Phase 2 LIBERTY ABPA AIRED Study

    Dec 1, 2025, 00:00

  • EE375 Economic Evaluation of Bispecific Antibodies in Europe: A Systematic Review

    Dec 1, 2025, 00:00

  • EPH66 Durable Medical Equipment and Ancillary Service Use in Rett Syndrome Management: A Global Comprehensive Review of Literature

    Dec 1, 2025, 00:00

  • CO181 Positioning of the Eluvia™, Drug-Eluting Stent in the Treatment of Peripheral Artery Disease (PAD) in Türkiye: Insights From a Specialist Panel Survey and Focus Group Study

    Dec 1, 2025, 00:00

  • PCR218 Social Media Listening Analysis of Cannabis Use in Patients With Inflammatory Bowel Disease

    Dec 1, 2025, 00:00

  • MSR160 Optimizing Patient-Reported Outcomes in German HTA: Addressing Key Challenges and Methodological Requirements

    Dec 1, 2025, 00:00

  • RWD87 From Data to Decisions: Enhancing Real-World Data Quality: A Survey of Health Data Producers in France

    Dec 1, 2025, 00:00

  • HTA257 Non-Proportional Hazards Network Meta-Analysis in NICE Technology Appraisals Prevalence and Insights

    Dec 1, 2025, 00:00

  • EPH189 Prevalence of Meningococcal Carriage by Serogroup in Adolescents and Young Adults: A Global Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EE501 Healthcare Costs of Mammography Screening and Breast Cancer Treatment: A Registry-Based Study From Norway

    Dec 1, 2025, 00:00

  • MT22 Global Evaluation of Flexible Cysto-Nephroscope Usage Patterns in Percutaneous Nephrolithotomy Procedures

    Dec 1, 2025, 00:00

  • HPR106 Gender-specific Drug Prices in Germany: A Comparative Analysis

    Dec 1, 2025, 00:00

  • PCR74 Enhancing Patient Experience of Subcutaneous Administration in Oncology: Development of a Dedicated Patient-Reported Experience Measure (PREM) Questionnaire Based on a Structured and Collaborative Approach

    Dec 1, 2025, 00:00

  • HTA81 Comparing Clinical Benefit Criteria in Health Technology Assessment of Oncology Drugs in the Netherlands and Europe: Driving Real Value or Inequal Access?

    Dec 1, 2025, 00:00

  • CO101 Estimating the Long-Term Impact of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Treatments on the Annual Decline of Percent-Predicted Forced Expiratory Volume in One Second (ppFEV1) Compared to Established Clin ...

    Dec 1, 2025, 00:00

  • CO44 Clinical Effectiveness and Safety of Second-Line Therapies for Immune Thrombocytopenia (ITP): A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HTA191 Identifying Methods Used Within Early Value Assessments for NICE: Results of a Scoping Review

    Dec 1, 2025, 00:00

  • EPH239 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Squamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • CO26 Bayesian Dynamic Borrowing to Enhance Evidence for New Therapies

    Dec 1, 2025, 00:00

  • CO255 Treatments for Children With Newly Diagnosed Medulloblastoma: A Systematic Review Of Randomized Controlled Trials

    Dec 1, 2025, 00:00

  • SA15 Balancing Rigor and Feasibility of Real-World Data Demands in Germany Within the EU HTA Context: How Fit for Purpose Is the Routine Practice Data Collection (Anwendungsbegleitende Datenerhebung, AbD)?

    Dec 1, 2025, 00:00

  • CO126 Gene Expression Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Lymph Node-Positive Early Breast Cancer: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR214 Using Directed Acyclic Graphs in Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison: Systematic Review and Methodological Insights

    Dec 1, 2025, 00:00

  • EE528 Impact of Comparator Type on Cost-Effectiveness Outcomes: Insights From ASMR III Evaluations in France

    Dec 1, 2025, 00:00

  • MSR72 Development of an AI-Powered Tool to Accelerate and Enhance Systematic Literature Reviews for Evidence-Based Decision Making in Clinical Research

    Dec 1, 2025, 00:00

  • HTA192 IMF: The Innovative Medicines Fund or the Interim Medicines Fund?

    Dec 1, 2025, 00:00

  • HTA226 Long-Term HTA Trends in Patient Organization Submissions to the NCPE and Future Perspectives

    Dec 1, 2025, 00:00

  • EPH127 Hospital Mortality in Germany Analysis of German Hospital Data From 2000 to 2019

    Dec 1, 2025, 00:00

  • HTA337 Too Advanced for STA, Too Common for HST? Navigating NICE Appraisals of Gene Therapies

    Dec 1, 2025, 00:00

  • PCR23 Assessing the Sensitivity of EQ-5D-5L and AQoL-4D to Disease Severity in Von Willebrand Disease: Findings From UK Cohort of the PIVOT-vWD Study

    Dec 1, 2025, 00:00

  • HTA41 Are Women’s Health Strategies Driving Change? A Review of NICE and SMC HTAs

    Dec 1, 2025, 00:00

  • CO178 Pegunigalsidase Alfa Elfabrio® as a Long-Term Enzyme Replacement Therapy in Adults With Fabry Disease: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HTA99 Costs and Their Impacts That Should Be Included in Health Technology Assessment of Remote Palliative Care

    Dec 1, 2025, 00:00

  • EPH238 The Health Impact of Pembrolizumab in Combination With Chemotherapy for the First-Line Treatment of Patients With Nonsquamous Metastatic Non-Small Cell Lung Cancer (mNSCLC) in Türkiye

    Dec 1, 2025, 00:00

  • EE231 Cost-Effectiveness Model of Ranolazine for Treating Chronic Stable Angina Patients From Kingdom of Saudi Arabia Perspective

    Dec 1, 2025, 00:00

  • EPH162 Modeling the Long-Term Bone Health Impact of TDF/FTC PrEP in Adolescent MSM

    Dec 1, 2025, 00:00

  • EE166 Cost Effectiveness and Budget Impact Analysis of Benralizumab for Treating Severe Uncontrolled Eosinophilic Asthma in Egypt

    Dec 1, 2025, 00:00

  • HSD104 Strengthening Routine Childhood Immunization Post-COVID: Global Strategies to Improve Coverage and Equity

    Dec 1, 2025, 00:00

  • CO164 Mind the Gap: A Need for Guidance on Modeling Disease Activity Outcomes in Economic Models

    Dec 1, 2025, 00:00

  • EPH34 Burden of Hospitalized Viral Respiratory Infections in Fran Insights From the 2022-2023 Season

    Dec 1, 2025, 00:00

  • Inequality Aversion in Health: Eliciting Aversion to Univariate Health Inequalities Across Different Health Distributions

    Dec 1, 2025, 00:00

  • MT18 From Development to Reimbursement Evidence-Generation Strategies for HealthTech in Europe

    Dec 1, 2025, 00:00

  • EPH177 Perspectives on Progress: A Qualitative Study of HIV Prevention Efforts in the Czech Republic

    Dec 1, 2025, 00:00

  • EE341 Does Insurance Value in Metastatic Breast Cancer Vary by Age Testing for Variation in Willingness to Pay for Novel Treatments Among Women in the US?

    Dec 1, 2025, 00:00

  • CO183 Potential Benefits of Universal Influenza Vaccination on Health Outcomes and Costs in Mexico

    Dec 1, 2025, 00:00

  • RWD108 Integrating Agentic AI With LLM Workflows for Cohort Comparison in Healthcare Analytics

    Dec 1, 2025, 00:00

  • EPH234 The Estimation of the Prevalent Presymptomatic Type 1 Diabetes Population in Germany Using a Patient Funnel Model

    Dec 1, 2025, 00:00

  • MT12 Cost Impact of the Porcine Urinary Bladder Matrix in Patients With Diabetic Foot Ulcer in the United Kingdom

    Dec 1, 2025, 00:00

  • SA57 Internal Validation of Type 2 Diabetes and Cardiovascular Events Incidences in the Core Obesity and Diabetes Model

    Dec 1, 2025, 00:00

  • EE530 Impact Of Dupilumab Treatment On Healthcare Resource Utilization in Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study

    Dec 1, 2025, 00:00

  • EE538 Impact of Nirsevimab on the Health Burden and Costs of Respiratory Syncytial Virus (RSV) in the Infant Population From the Healthcare System in Argentina

    Dec 1, 2025, 00:00

  • HTA162 German HTA Outcomes for Rare Disease Drugs When Orphan Designation Does Not Legally Determine Added Benefit

    Dec 1, 2025, 00:00

  • HSD95 Real-World Hospital Stays Description and Cost Analysis of Immune Checkpoint Inhibitors (ICIs) Using National PMSI Data in France

    Dec 1, 2025, 00:00

  • HTA44 Assessing Readiness for the EU-HTA Regulation: Insights From Market Access Experts Across Europe

    Dec 1, 2025, 00:00

  • EE297 Cost-Utility Analysis of Adding Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors or Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists to Standard Therapy in Thai Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Diseas ...

    Dec 1, 2025, 00:00

  • EPH121 Healthcare Resource Use in Transthyretin Amyloidosis Cardiomyopathy: An Observational Study in the UK Clinical Setting Using Electronic Health Records

    Dec 1, 2025, 00:00

  • EE107 Budget Impact of Including Cannabis-Based Products in Brazil’s Public Health System: A Scenario Analysis

    Dec 1, 2025, 00:00

  • RWD103 Incidence of Adverse Events and Costs Among Patients Initiating Treatment for Myasthenia Gravis: A Real-World Analysis

    Dec 1, 2025, 00:00

  • EE39 Addressing the Impact of Alzheimer’s Disease on Care Capacity in the Netherlands: Implications for Health Technology Assessment

    Dec 1, 2025, 00:00

  • CO62 Comparison of Persistence Rates: Tildrakizumab vs. Adalimumab/Ustekinumab Based on a German Longitudinal Prescription Database (LRx) of Social Health Insurance Patients in Outpatient Care

    Dec 1, 2025, 00:00

  • PCR148 Listening to the Voice of the Patient: Insights From a Survey on the Burden of Recurrent Respiratory Papillomatosis in the United States

    Dec 1, 2025, 00:00

  • EE100 Budget Impact Analysis of the EPOCA Telemonitoring System for Elderly Patients in France

    Dec 1, 2025, 00:00

  • SA55 Innovative Approaches to Real-World Evidence Generation: The Role of Italian Community Pharmacies

    Dec 1, 2025, 00:00

  • EE59 Assessing the Cost-Effectiveness of Semaglutide 24 mg in the Management of People With Obesity and Knee Osteoarthritis in the UK

    Dec 1, 2025, 00:00

  • EE376 Economic Evaluation Of Cefiderocol for the Treatment of Carbapenem-Resistant Acinetobacter Baumannii in Italy Using Real-World Evidence

    Dec 1, 2025, 00:00

  • Zero Dollar Copay Pharmacy Benefit Decreases Healthcare Expenditures Among Members With Type 2 Diabetes of Blue Cross Blue Shield of Louisiana

    Dec 1, 2025, 00:00

  • EE17 A Cost-Utility Analysis of Sparsentan for the Treatment of Immunoglobulin A Nephropathy in the UK

    Dec 1, 2025, 00:00

  • EPH150 Is Europe and European Evidence Development an Afterthought in Pharmaceutical Early Stage Development Decisions? An Exploratory Qualitative Survey

    Dec 1, 2025, 00:00

  • EE14 A Cost-Minimization and Budget Impact Analysis of NT-proBNP Screening for Systematic Sclerosis-Related Pulmonary Arterial Hypertension in an Australian Healthcare Setting

    Dec 1, 2025, 00:00

  • P53 Exploring the Ability of Generative AI to Interpret and Report Comprehensive NMA Results: A Step Towards the Automation of NMA Reports

    Dec 1, 2025, 00:00

  • EE543 Impact of Temporarily Implanted Nitinol Device in the Treatment of Urinary Symptoms in Patients With Benign Prostatic Obstruction in Spain

    Dec 1, 2025, 00:00

  • MT28 Impact of RFID-Enabled Unit-Level Traceability on Resource Utilization and Quality Assurance in Prefilled Syringe Production

    Dec 1, 2025, 00:00

  • P17 Implementation of Patient Experience Data in Clinical Trial Design: A Literature Review and Semi-Structured Interviews

    Dec 1, 2025, 00:00

  • EPH215 Site-Specific Wastewater-Based Surveillance in Early Detection of COVID-19 New Cases and Prediction of Mass Testing Outcomes in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • EE15 A Cost-Minimization and Budget Impact Analysis of NT-proBNP Screening Test for Risk Assessment and Monitoring of Pulmonary Arterial Hypertension (PAH) Patients in Australian Healthcare Setting

    Dec 1, 2025, 00:00

  • SA82 Real-World Findings From the Provent Study of Dupilumab Therapy for Severe Asthma: 2-Year Analysis

    Dec 1, 2025, 00:00

  • HTA65 Caregiver Quality of Life in Orphan Drug Health Technology Assessment Submissions in Europe: A Comparative Analysis

    Dec 1, 2025, 00:00

  • EE552 Indirect Treatment Comparisons in Economic Evaluations Submitted to the French Health Authority (CEESP) Since 2014

    Dec 1, 2025, 00:00

  • EE102 Budget Impact and Clinical Outcomes of Energy- and Nutrient-Dense Formulas in Pediatric Disease-Related Malnutrition: A Middle Eastern Analysis

    Dec 1, 2025, 00:00

  • SA14 Assessing the Use of Artificial Intelligence in Publication-Grade Research: A Literature Review of Applications in HEOR

    Dec 1, 2025, 00:00

  • EPH224 Survival Trends in Multiple Myeloma by Treatment Era in the United States

    Dec 1, 2025, 00:00

  • EE715 The Impact of Real-World Standard-Dose Influenza Vaccine Effectiveness on the Cost-Effectiveness of High-Dose Influenza Vaccine: A Case Study in Japan

    Dec 1, 2025, 00:00

  • P27 Predicting Treatment Effect on the Loss of Ability to Rise From Floor in Duchenne Muscular Dystrophy Using Individual Trajectories: An Application of Joint Modeling in FOR-DMD

    Dec 1, 2025, 00:00

  • SA22 Confirmation of Diagnosis Method for Robust Participant Selection in Direct-to-Patient Real-World Evidence Studies

    Dec 1, 2025, 00:00

  • MSR24 AI-Driven Simulation of FDA DCOA Review to Inform Evidence Planning and Regulatory Strategy

    Dec 1, 2025, 00:00

  • MSR120 How Chinese Restaurants Can Help With Robust Preference Insights: A Novel Dirichlet Mixture Model to Account for Complex Heterogeneity in Individual Preference Weights

    Dec 1, 2025, 00:00

  • CO223 Symptom Relief With Vonoprazan Treatment in Gastroesophageal Reflux Disease Patients With Diabetes in China: Post Hoc Analysis of the VIEW Study

    Dec 1, 2025, 00:00

  • EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • HSD96 Real-World Study on Length of Hospital Stay and Economic Burden of AECOPD Inpatients in a Traditional Chinese Medicine Hospital in China

    Dec 1, 2025, 00:00

  • PCR175 Patient Perspectives on the Lifelong Impact of Preterm Birth in Chronic Respiratory Disease Care

    Dec 1, 2025, 00:00

  • HTA267 Patient-Centered Hearing Technology Assessment: Integrating ICF Into Multicriteria Decision Making

    Dec 1, 2025, 00:00

  • Understanding the Role of Clinical and Functional Needs in Home-Visit Nursing Effectiveness: Evidence From South Korea

    Dec 1, 2025, 00:00

  • EE229 Cost-Effectiveness Evaluation of Combined Cervical Cancer Screening With CINtec PLUS in the Czech Republic

    Dec 1, 2025, 00:00

  • HPR131 Launches of Oncology Products in LATAM vs. the United States

    Dec 1, 2025, 00:00

  • HPR193 The Alignment Between Technology Incorporations and Actual Health Needs

    Dec 1, 2025, 00:00

  • CO123 Fezolinetant Veoza™ As a Nonhormonal Treatment for Moderate to Severe Vasomotor Symptoms in Postmenopausal Women: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • EE195 Cost-Effectiveness Analysis of CYP2C19 Genotype-Guided Antiplatelet Therapy for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in the Netherlands

    Dec 1, 2025, 00:00

  • PCR261 Utilizing the Patient-Specific Needs Evaluation for Data-Supported and Individualized Treatment (UNITE)

    Dec 1, 2025, 00:00

  • EE452 Exit Strategies in Patients With Stable MS: Cost-Effectiveness of Extended Interval Dosing of Ocrelizumab and Natalizumab vs. De-escalating to Cladribine

    Dec 1, 2025, 00:00

  • RWD38 Comparative Analysis of Safety of Targeted NSCLC Therapies Using the FDA Adverse Event Reporting System (FAERS) Differing Experience of Healthcare Providers (HCP) From EU vs. US

    Dec 1, 2025, 00:00

  • MSR207 Turning the Tables: AI Halves Table Extraction Time in HEOR Systematic Reviews

    Dec 1, 2025, 00:00

  • EPH87 Estimating the Eligible Population for Anti-Amyloid Therapy in Finland

    Dec 1, 2025, 00:00

  • CO173 OncoLlama: Quantifying Cancer Inequalities at Population Scale Using Large Language Models for Clinical Text Abstraction

    Dec 1, 2025, 00:00

  • PCR189 Predicting Italian EQ-5D-3L Health State Utilities From UK Values: Validation of a Nonlinear Utility Adjustment Model Using Real-World Evidence

    Dec 1, 2025, 00:00

  • EE438 Evaluating the Cost-Effectiveness of Nasal Adrenaline Spray vs. Adrenaline Autoinjector for Treatment of Anaphylaxis: A Cost-Utility Modeling Approach

    Dec 1, 2025, 00:00

  • EE287 Costs and Number Needed to Treat (NNT) to Achieve Improvements With C5 Inhibitors in Generalized Myasthenia Gravis From the Japanese Healthcare Perspective: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • HTA136 Evaluating the Value Elements Considered in Health Technology Assessments of Paroxysmal Nocturnal Hemoglobinuria Treatments: A Targeted Review

    Dec 1, 2025, 00:00

  • HPR83 Evolution of Pharmaceutical Pricing and Reimbursement Agreements in Spain Over the Last 10 Years: Towards an Outcomes-Based Approach

    Dec 1, 2025, 00:00

  • HTA66 CAR-T Therapy in Asia-Pacific: Is It Reimbursed in Your Country?

    Dec 1, 2025, 00:00

  • PT12 Understanding the Consequences of International Reference Pricing on Cancer Immunotherapy in Europe: A 10-Year Price Corridor Analysis

    Dec 1, 2025, 00:00

  • PT41 Health Economic Evaluations of Prevention and Management Strategies for Cholangiocarcinoma: A Systematic Review

    Dec 1, 2025, 00:00

  • RWD159 Real-World Insights Into Breast Cancer in the UK: Findings From UK EHR-Derived Data

    Dec 1, 2025, 00:00

  • EPH240 The Health Impact of Pembrolizumab Plus Chemotherapy in the First-Line Treatment for Metastatic Triple-Negative Breast Cancer (TNBC) in Türkiye

    Dec 1, 2025, 00:00

  • PCR20 Are You Implementation Ready? An Alternative Patient And Healthcare System-Centered Model For Pharma

    Dec 1, 2025, 00:00

  • HTA116 The Challenges of Evaluating Individualized Therapies in Health Technology Assessment: A Thematic Review

    Dec 1, 2025, 00:00

  • SA68 Methodology and Challenges of Network Meta-Analysis in Health Technology Assessment of Medical Devices: A Case Study of Drug-Eluting Stents

    Dec 1, 2025, 00:00

  • EPH113 Fostamatinib-Induced Hepatomegaly: A Novel Signal Identified Through US Food and Drug Administration Adverse Event Reporting System (FAERS) Database

    Dec 1, 2025, 00:00

  • HPR173 Regulatory Landscape Challenges and Trends in the Adoption of Digital Endpoints in Clinical Trials: A Scoping Review

    Dec 1, 2025, 00:00

  • HPR199 The Enduring Economic Burden of COVID-19 and the Value of Vaccination Strategies in High-Income Countries

    Dec 1, 2025, 00:00

  • HTA279 Reassessing NICE's Highly Specialized Technologies (HST) Criteria: A Retrospective Review of Borderline and Approved Appraisals Under the Revised Framework

    Dec 1, 2025, 00:00

  • HTA147 Focus on Two Years of Economic Opinions on Solid Cancers (2023-2024): What Are the Specific Features vs. 2021-2022?

    Dec 1, 2025, 00:00

  • EE154 Correlation Between Ultra-Orphan Drug Costs Cost-Effectiveness Metrics and Disease Prevalence

    Dec 1, 2025, 00:00

  • EE353 Economic Burden and Health-Related Quality of Life Associated With Schizophrenia in Saudi Arabia

    Dec 1, 2025, 00:00

  • RWD104 Incidence of Intracerebral Hemorrhage in Patients With Mild Cognitive Impairment or Alzheimer’s Dementia in United States Veterans

    Dec 1, 2025, 00:00

  • EE498 Healthcare Burden Among Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE24 A Nonactive Implant for the Treatment of Chronic Gastro-esophageal Reflux Disease: A Cost-Effectiveness Evaluation From the Perspective of German Healthcare

    Dec 1, 2025, 00:00

  • HSD73 Medication Patterns of Traditional Chinese Medicine for Chronic Obstructive Pulmonary Disease: A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • EPH202 Quantifying the Economic Burden of Undiagnosed Sleep Apnea in India’s Productive Population: A Health Economic Modeling Approach

    Dec 1, 2025, 00:00

  • HTA357 Vignette-Based Economic Models in UK HTA Submissions: Valuable Tool or Just NICE in Theory?

    Dec 1, 2025, 00:00

  • EE547 Improving the Transferability of Global RCT Data to Inform Cost-Effectiveness Models in Japan: A Structured Framework for C2H Submissions

    Dec 1, 2025, 00:00

  • PCR94 Exploring the Promise of Generative AI for Coding and Analyzing Qualitative Patient Data: Results From a Pilot Study in Non-Hodgkin’s Lymphoma

    Dec 1, 2025, 00:00

  • RWD156 Real-World Evidence Study on Healthcare Resource Utilization (HCRU) Among Cancer Patients in the Helsinki and Uusimaa (HUS) Region, Finland

    Dec 1, 2025, 00:00

  • MSR69 Developing an HER-Based Multifeature Machine Learning Model to Identify Lung Cancer Subtype

    Dec 1, 2025, 00:00

  • MSR75 AI Time and Motion - Analysis of the Accuracy and Efficiency of AI for HTA-Standard SLRs

    Dec 1, 2025, 00:00

  • HSD90 Potential Operational Efficiencies of a Combination Influenza and COVID-19 Vaccine in US Pharmacies

    Dec 1, 2025, 00:00

  • CO111 Evaluating Therapeutic Landscape in Radio-Iodine-Refractory–Differentiated Thyroid Cancer (DTC): A Bayesian Network Meta-Analysis of Clinical Efficacy

    Dec 1, 2025, 00:00

  • CO84 Effective Use of Reconstructed Survival Data for Individual-Level Correlation Assessment in Oncology: A Case Study in Metastatic-Hormone Sensitive Prostate Cancer (mHSPC)

    Dec 1, 2025, 00:00

  • SA2 A Patient-Level Simulation to Bridge Data Gaps in Cost-Effectiveness Modeling of B-VEC for Dystrophic Epidermolysis Bullosa

    Dec 1, 2025, 00:00

  • PCR199 Qualitative Assessment of Women’s Experiences of Sleep Disturbances Associated With Menopause to Evaluate Content Validity of Patient-Reported Outcomes

    Dec 1, 2025, 00:00

  • EPH80 Epidemiology and Outcomes in a Linked Cohort of Cancer Pathology and Electronic Medical Records From the PHARMO Data Network

    Dec 1, 2025, 00:00

  • MSR125 Human Alignment on Evaluating LLMs for Literature Review Extraction

    Dec 1, 2025, 00:00

  • HTA358 Weighting the OrPhar-SEFH MCDA Framework for Its Use in Ultrarare Kidney Diseases

    Dec 1, 2025, 00:00

  • EE598 Optimal Utilization of Robotic-Assisted Surgery in the NHS: A System-Level Economic Evaluation Model

    Dec 1, 2025, 00:00

  • EPH107 Exploring the Impact of Dupilimab on the Patient Care Pathways: GHG Emissions of Patients With Moderate-to-Severe COPD In France

    Dec 1, 2025, 00:00

  • RWD123 Medication Use in Indolent Systemic Mastocytosis (ISM) in Germany Prior to Avapritinib EMA Approval

    Dec 1, 2025, 00:00

  • SA95 The Journey to Diagnosis for Patients With CIDP: Results From a Real-World International Survey

    Dec 1, 2025, 00:00

  • P7 Life-Cycle Economic Modeling to Determine the Evolving Value of a Tumor-Agnostic Precision Oncology Therapy With Conditional Marketing Authorization

    Dec 1, 2025, 00:00

  • PCR257 Uptake and Early Removal of Hormonal Implant Contraceptive Among Women Attending the Family Planning Clinic in a Tertiary Institution in West Africa January 2018-December 2020

    Dec 1, 2025, 00:00

  • EE489 Health Economic Assessment of Cefepime-Enmetazobactam for Treating Complicated Urinary Tract Infections: A German Payer Perspective

    Dec 1, 2025, 00:00

  • EE442 Evaluating the Economic Impact of Worksite Physical Activity Interventions in Denmark: An Employer’s Perspective

    Dec 1, 2025, 00:00

  • EE541 Impact of Real-World Effectiveness vs. Previous Assumptions on Estimates of Economic and Clinical Benefit of 20-Valent Pneumococcal Conjugate Vaccine in Adults Across Countries

    Dec 1, 2025, 00:00

  • HTA86 Comprehensive Clinical Evaluation of Amphotericin B in the Treatment of Invasive Fungal Disease in China

    Dec 1, 2025, 00:00

  • CO36 Cardioprotective Medication Use Among Diabetic Patients With ASCVD in Qatar's Primary Care Setting

    Dec 1, 2025, 00:00

  • MSR186 Simulated Treatment Comparisons Using Jackknife Pseudo Values for Population-Adjusted Marginal Effect Estimation

    Dec 1, 2025, 00:00

  • EE30 A Review of Health Economic Modeling Challenges for Opioid Use Disorder Treatment in Prison Settings

    Dec 1, 2025, 00:00

  • MSR217 Using Propensity Weighting Methods With Real-World Data and Noncontrolled Extension Data From a Clinical Trial to Estimate Long-Term Treatment Effect: An Example in Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • EPH88 Estimating the Future Burden of Unvaccinated Girls Against Human Papilloma Virus (HPV) in Europe: A Modeling Study

    Dec 1, 2025, 00:00

  • HPR12 Accelerating Therapeutic Innovation: Early Results From France’s Accès Direct Scheme

    Dec 1, 2025, 00:00

  • EE278 Cost-Effectiveness of Supportive Exercise Interventions for Colorectal Cancer Surgery: An Economic Evaluation of the PREPARE-ABC Multicenter, Randomized, Controlled Trial

    Dec 1, 2025, 00:00

  • MSR215 Using Machine Learning to Enable Timely Postpartum Care by Reliably Detecting Deliveries

    Dec 1, 2025, 00:00

  • MSR130 Improving Indirect Treatment Comparisons via an Alternative MAIC Patient Weighting Method

    Dec 1, 2025, 00:00

  • HTA27 Advocating From the Margins: How Patient Input Aligns With Broader Evidence Tolerance in HTA Within Oncology

    Dec 1, 2025, 00:00

  • Author Reply

    Dec 1, 2025, 00:00

  • EE78 Broader Economic Effects of Investment in Cancer Control in Commonwealth Countries

    Dec 1, 2025, 00:00

  • EPH259 Trends and Characteristics of Thrombectomy Use in Acute Ischemic Stroke in Germany (2019-2024): Insights From National Claims Data

    Dec 1, 2025, 00:00

  • CO227 Systematic Literature Review and Bayesian Network Meta-Analysis of Sugemalimab Plus Chemotherapy vs. Other First-Line Treatments for Metastatic Non-Small Cell Lung Cancer Without Sensitizing eGFR, ALK, ROS1, or RET Alterations

    Dec 1, 2025, 00:00

  • CO241 The Impact of Generalized Anxiety Disorder on Comorbid Conditions: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR137 Leveraging NLP to Characterize Real-World Triptan Use and Adherence From Unstructured EHR

    Dec 1, 2025, 00:00

  • MSR31 Applying Simulation-Guided Trial Design Principles to Prospectively Plan Target Trial Emulation of a Cluster Randomized Trial for Vaccine Coverage

    Dec 1, 2025, 00:00

  • HTA285 Reimbursement Trends Across Global Markets in 2024

    Dec 1, 2025, 00:00

  • EE759 Workforce and Environmental Impact of Home-Based vs. Hospital-Based Administration of Second-Line MS Therapies in the Netherlands: A Comparative Analysis of Personnel Time and Carbon Footprint

    Dec 1, 2025, 00:00

  • HSD97 Real-World Treatment Patterns Among Patients With Relapsed or Refractory (R/R) NPM1 Mutated (NPM1m) Acute Myeloid Leukemia (AML) in the United States (US)

    Dec 1, 2025, 00:00

  • HSD114 Treatment Characteristics of Breast Cancer Patients per HER2/HR Status in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis

    Dec 1, 2025, 00:00

  • HTA181 How the EU JCA Could Interface With Regional Pricing Alliances (BeNeLuxA, Nordic Forum, Valletta Group) and EU-Level Procurement Under the Critical Medicines Act

    Dec 1, 2025, 00:00

  • EE191 Cost-Consequence Analysis of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Treatment vs. Large-Volume Paracentesis (LVP) in the Management of Refractory Ascites: Preliminary Results Overview From an Italian Healthcare Perspecti ...

    Dec 1, 2025, 00:00

  • EE348 Early Stage Health Economic Evaluation of IMMUTOL Gene Therapy for Relapsing/Remitting Multiple Sclerosis in the Netherlands

    Dec 1, 2025, 00:00

  • RWD128 Obesity and MASH in the UK

    Dec 1, 2025, 00:00

  • PCR44 CKDL5 Deficiency Disorder: Caregiver’s Perception of Clinical Symptoms Disease Management and Its Impact on Quality-of-life

    Dec 1, 2025, 00:00

  • EPH51 Comparative Prevalence of Suicidal Ideation and Self-Harm History: Rexulti vs. Other Oral Atypical Antipsychotics

    Dec 1, 2025, 00:00

  • MT16 Evaluating Digital Health Tools in the UK for Type 1/2 Diabetes: An Overview of the Evidence Critiques

    Dec 1, 2025, 00:00

  • HTA246 Navigating Large Evidence Bases for MTEP Submissions

    Dec 1, 2025, 00:00

  • HTA250 Navigating Uncharted Waters: Challenge of Anticipating Technologies Subject to Environmental Considerations in Future HTA

    Dec 1, 2025, 00:00

  • EE198 Cost-Effectiveness Analysis of Fixed-Dose Combination Rosuvastatin and Ezetimibe vs. Simvastatin Plus Ezetimibe for the Treatment of Hypercholesterolemia in Patients at High Risk and Very High Risk of Cardiovascular Disease in Algeria ...

    Dec 1, 2025, 00:00

  • CO198 Quantifying the Therapeutic Benefit of External Beam Radiotherapy in Uterine Serous Carcinoma: A Real-World Study

    Dec 1, 2025, 00:00

  • MSR122 How Far Have We Come With EQ-5D-5L Value Sets? An Updated Systematic Literature Review of 55 Valuation Studies

    Dec 1, 2025, 00:00

  • HPR75 Evaluating the Costs and Benefits of Innovative Pricing and Payment Models in Europe

    Dec 1, 2025, 00:00

  • HTA217 Landscape Analysis of Initiatives to Improve Access to Orphan Drugs Led by Industry Patient and Academic Stakeholders

    Dec 1, 2025, 00:00

  • EPH74 Epidemiological Burden of Osteoarthritis in Eastern, Central, and Western Europe Between 1990 and 2021

    Dec 1, 2025, 00:00

  • EPH4 A Person-Centered Approach: Exploring Social Support Network and Mental Health Among Shoebox House Residents in Hong Kong

    Dec 1, 2025, 00:00

  • EE481 Global Economic Burden of Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EE313 Cost-Utility of Intramuscular Testosterone for Men and Male Adolescents With Organic Hypogonadotropic Hypogonadism in Brazil

    Dec 1, 2025, 00:00

  • HPR103 From Evidence to Enforcement? Implications of the 2025 SVR Report for Pharmaceutical Pricing and Orphan Drug Policy in Germany

    Dec 1, 2025, 00:00

  • SA75 Performance of Large Language Model Clinical Data Extraction by Data Domain: A Rapid Systematic Review

    Dec 1, 2025, 00:00

  • EPH10 A Systematic Literature Review to Identify Risk Factors and Symptoms of Long COVID-19 in Adult Indian Patients

    Dec 1, 2025, 00:00

  • HPR140 MCDA Tool Adoption in Egypt: Room for Sustainability and Accessibility

    Dec 1, 2025, 00:00

  • SA28 Decoding Diagnosis Delay in Juvenile Idiopathic Arthritis (JIA)

    Dec 1, 2025, 00:00

  • EPH251 The PHEBUS Study: A Retrospective Analysis of the Burden of Pneumococcal Infections in the Pediatric Population Using the French Hospital Discharge Database (PMSI)

    Dec 1, 2025, 00:00

  • HPR239 Which Country Is Currently Reporting the Lowest Global Prices for Semaglutide, and Why?

    Dec 1, 2025, 00:00

  • CO27 Bayesian Network Meta-Analysis of Weight Loss Efficacy for GLP-1 Receptor Agonists and Tirzepatide

    Dec 1, 2025, 00:00

  • HPR152 Orphan Drug Approvals in the US and Europe: A 2-Year Comparison

    Dec 1, 2025, 00:00

  • OP18 Overview of Hospital Management of Patients Treated With Thoracic Endovascular Repair (TEVAR) and Revascularization of the Left Subclavian Artery in France Based on the PMSI

    Dec 1, 2025, 00:00

  • PCR83 Evaluating the Role of Disease-Specific Patient-Reported Outcomes in HTA Submissions for Rare Conditions: A Comparative Case Study of Narcolepsy and Phenylketonuria

    Dec 1, 2025, 00:00

  • EPH204 Real-life-Persistence to Antifibrotic Treatments in the French Population

    Dec 1, 2025, 00:00

  • HSD43 Environmental Impact of Intravenous vs. Oral Chemotherapy in Fran A 1000-Patient Model-Based Assessment

    Dec 1, 2025, 00:00

  • HTA318 The HTA Landscape of Orphan Products in the UK Between 2019 and 2024

    Dec 1, 2025, 00:00

  • HPR105 From Promise to Practi Addressing the Systemic Challenges of Underinvestment in Prevention

    Dec 1, 2025, 00:00

  • CO112 Evaluation of Health-Related Quality of Life (HRQoL) Among Patients Treated With Lifileucel After Progression on Immune Checkpoint Inhibitors (ICIs) and Targeted Therapies: Analyses From the C-144-01 Trial

    Dec 1, 2025, 00:00
  • 1 (current)
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • »